Sandra J. Meech

1.2k total citations
21 papers, 989 citations indexed

About

Sandra J. Meech is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Sandra J. Meech has authored 21 papers receiving a total of 989 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in Sandra J. Meech's work include Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Sandra J. Meech is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Sandra J. Meech collaborates with scholars based in United States, Australia and Poland. Sandra J. Meech's co-authors include Richard C. Duke, Stephen P. Hunger, Jerome Schaack, Tammy E. Hedlund, Rebecca Benner, Marilyn Johnson, Linda Jacobson, Christopher L. Moertel, Adriana Weinberg and Nigel S. Key and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Sandra J. Meech

21 papers receiving 951 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra J. Meech United States 14 380 330 302 159 145 21 989
Paolo Peterlongo Italy 13 231 0.6× 206 0.6× 450 1.5× 166 1.0× 207 1.4× 31 1.0k
Chung-Che Chang United States 18 529 1.4× 236 0.7× 231 0.8× 83 0.5× 255 1.8× 49 1.0k
Kathryn A. Kolquist United States 12 467 1.2× 449 1.4× 634 2.1× 126 0.8× 92 0.6× 20 1.5k
S A Cannistra United States 15 324 0.9× 368 1.1× 405 1.3× 107 0.7× 96 0.7× 24 1.1k
Yuichiro Hamanaka Japan 16 559 1.5× 319 1.0× 389 1.3× 76 0.5× 92 0.6× 39 1.2k
Diana F. Hausman United States 18 584 1.5× 472 1.4× 538 1.8× 203 1.3× 126 0.9× 40 1.6k
Vito Rodolico Italy 24 457 1.2× 258 0.8× 487 1.6× 125 0.8× 126 0.9× 79 1.6k
Jill Giles‐Komar United States 17 164 0.4× 632 1.9× 349 1.2× 211 1.3× 68 0.5× 30 1.3k
Solveig G. Ericson United States 20 883 2.3× 182 0.6× 227 0.8× 213 1.3× 67 0.5× 67 1.4k
K. Witter Germany 15 415 1.1× 397 1.2× 213 0.7× 67 0.4× 111 0.8× 57 957

Countries citing papers authored by Sandra J. Meech

Since Specialization
Citations

This map shows the geographic impact of Sandra J. Meech's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra J. Meech with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra J. Meech more than expected).

Fields of papers citing papers by Sandra J. Meech

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra J. Meech. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra J. Meech. The network helps show where Sandra J. Meech may publish in the future.

Co-authorship network of co-authors of Sandra J. Meech

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra J. Meech. A scholar is included among the top collaborators of Sandra J. Meech based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra J. Meech. Sandra J. Meech is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Belani, Chandra P., John Nemunaitis, Abraham Chachoua, et al.. (2013). Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biology & Therapy. 14(7). 557–563. 31 indexed citations
2.
Millward, Michael, Craig Underhill, Sandra J. Meech, et al.. (2013). Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. British Journal of Cancer. 108(10). 1998–2004. 55 indexed citations
3.
Manegold, C., Nico van Zandwijk, A. Szczęsna, et al.. (2011). A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 23(1). 72–77. 117 indexed citations
4.
Humphrey, Rachel, Kathleen M. Dohoney, James H. Doroshow, et al.. (2011). Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer. JNCI Journal of the National Cancer Institute. 103(16). 1222–1226. 99 indexed citations
5.
Hirsh, Vera, Luis Paz‐Ares, Michael Boyer, et al.. (2011). Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(19). 2667–2674. 116 indexed citations
6.
Lai, Ricky Y. K., Larry D. Recht, David A. Reardon, et al.. (2010). Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).. Journal of Clinical Oncology. 28(15_suppl). 2014–2014. 10 indexed citations
7.
Gandhi, Sachin, et al.. (2005). Combined Computed Tomography-Guided Radiofrequency Ablation and Brachytherapy in a Child With Multiple Recurrences of Wilms' Tumor. Journal of Pediatric Hematology/Oncology. 27(7). 377–379. 10 indexed citations
8.
Sholler, Giselle L. Saulnier, François I. Luks, Shamlal Mangray, & Sandra J. Meech. (2005). Advanced Small Cell Carcinoma of the Ovary in a Pediatric Patient With Long-Term Survival and Review of the Literature. Journal of Pediatric Hematology/Oncology. 27(3). 169–172. 21 indexed citations
9.
Modiano, Jaime F., Juan Sun, Julie Lang, et al.. (2004). Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells. Clinical Immunology. 112(1). 54–65. 11 indexed citations
10.
Liang, Xiayuan, Sandra J. Meech, Lorrie F. Odom, et al.. (2004). Assessment of t(2;5)(p23;q35) Translocation and Variants in Pediatric ALK+ Anaplastic Large Cell Lymphoma. American Journal of Clinical Pathology. 121(4). 496–506. 35 indexed citations
11.
Meech, Sandra J.. (2004). Contemporary Quilts: Design, Surface and Stitch. 10 indexed citations
12.
Liang, Xiayuan, Sandra J. Meech, Lorrie F. Odom, et al.. (2004). Assessment of t(2;5)(p23;q35) Translocation and Variants in Pediatric ALK+ Anaplastic Large Cell Lymphoma. American Journal of Clinical Pathology. 121(4). 496–506. 36 indexed citations
13.
Liang, Xiayuan, Loren E. Golitz, Bruce R. Smoller, et al.. (2002). Association of Expression of CD44v6 With Systemic Anaplastic Large Cell Lymphoma. American Journal of Clinical Pathology. 117(2). 276–282. 6 indexed citations
14.
Shellman, Yiqun G., et al.. (2002). Regulation of Fas-Mediated Apoptosis by N-ras in Melanoma. Journal of Investigative Dermatology. 119(3). 556–561. 17 indexed citations
15.
Meech, Sandra J., et al.. (2001). Reversible Resistance to Apoptosis in Cutaneous T Cell Lymphoma. Annals of the New York Academy of Sciences. 941(1). 46–58. 33 indexed citations
16.
Meech, Sandra J., Loris McGavran, Lorrie F. Odom, et al.. (2001). Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4–anaplastic lymphoma kinase gene fusion. Blood. 98(4). 1209–1216. 68 indexed citations
17.
Hedlund, Tammy E., Sandra J. Meech, Andrew S. Kraft, et al.. (1999). Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death and Differentiation. 6(2). 175–182. 51 indexed citations
18.
Duke, Richard C., et al.. (1999). Transplantation of cells and tissues expressing Fas ligand. Transplantation Proceedings. 31(3). 1479–1481. 9 indexed citations
19.
Leon, Ronald P., Tammy E. Hedlund, Sandra J. Meech, et al.. (1998). Adenoviral-mediated gene transfer in lymphocytes. Proceedings of the National Academy of Sciences. 95(22). 13159–13164. 119 indexed citations
20.
Johnson, Marilyn, Rachelle Nuss, Nigel S. Key, et al.. (1996). Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. The Journal of Pediatrics. 128(3). 319–323. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo Peterlongo Breakdown of academic impact, for papers by Chung-Che Chang Breakdown of academic impact, for papers by Kathryn A. Kolquist Breakdown of academic impact, for papers by S A Cannistra Breakdown of academic impact, for papers by Yuichiro Hamanaka Breakdown of academic impact, for papers by Diana F. Hausman Breakdown of academic impact, for papers by Vito Rodolico Breakdown of academic impact, for papers by Jill Giles‐Komar Breakdown of academic impact, for papers by Solveig G. Ericson Breakdown of academic impact, for papers by K. Witter
Rankless by CCL
2026